Zobrazeno 1 - 10
of 23
pro vyhledávání: '"R. Morón-Romero"'
Autor:
M.E. Rodríguez-Delgado, A.M. Echeverría-Álvarez, M. Colmenero-Ruiz, R. Morón-Romero, A. Cobos-Vargas, A. Bueno-Cavanillas
Publikováno v:
Enfermería Intensiva (English ed.).
Autor:
M.E. Rodríguez-Delgado, A.M. Echeverría-Álvarez, M. Colmenero-Ruiz, R. Morón-Romero, A. Cobos-Vargas, A. Bueno-Cavanillas
Publikováno v:
Enfermería Intensiva.
Autor:
J Cabeza-Barrera, R Álvarez-Sánchez, S Portillo-Haro, E Yuste-Ossorio, J García Villanova, M Núñez-Núñez, R Morón-Romero, N Chueca
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Exposure to beta-lactam antibiotics due to their hydrophilic properties is widely known to be influenced by the typical pharmacokinetic alterations in critical patients, such as increased volume of distribution and increased
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
R Morón-Romero, S Ruiz-Fuentes, C García-Fernandez, S. Belda-Rustarazo, C Gómez-Peña, P Gómez-Nieto
Publikováno v:
Eur J Hosp Pharm
Background The prescriptions of biologics are increasing as new indications and drugs are authorised. Since biosimilar drugs were introduced in the pharmaceutical market, they have become an alternative to continuing with the demand at competitive co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09bb1fd73e7a5ef79e21479009ea8609
https://europepmc.org/articles/PMC7535604/
https://europepmc.org/articles/PMC7535604/
Autor:
R Morón Romero, LJ Martinez, CL Dávila Fajardo, X Diaz Villamarin, M Valle Corpas, D Blanquez Martinez, MJ Soto Pino, J Cabeza Barrera, E Raya Alvarez, Mdc Gonzalez Medina
Publikováno v:
European Journal of Hospital Pharmacy. 23:A142.1-A142
Background Tocilizumab (TCZ) is a humanised monoclonal antibody inhibitor of interleukin 6 receptor, indicated in combination with methotrexate in the treatment of rheumatoid arthritis (RA) in patients with inadequate response or intolerance to prior
Autor:
C Gómez-Peña, C García Fernández, M Valle Corpas, R Morón Romero, J Cabeza-Barrera, Mdc Gonzalez Medina, CL Dávila Fajardo, X Díaz-Villamarín, I Casas Hidalgo, Clara Marin
Publikováno v:
European Journal of Hospital Pharmacy. 23:A30.2-A31
Background Fampridine has been approved for improvement in walking capacity (WC) in multiple sclerosis adult patients with Expanded Disability Status Scale (EDSS) score of 4–7. Purpose To evaluate the effectiveness of fampridine in WC in MS patient
Autor:
R Morón Romero, J Cabeza Barrera, Mdc Gonzalez Medina, C García Fernández, C Gómez Peña, I Casas Hidalgo, M Valle Corpas
Publikováno v:
European Journal of Hospital Pharmacy. 23:A84.2-A85
Background Medication reconciliation (MR) is known to minimise medicine errors and reduce morbidity in hospitalised patients. This process aims to identify and solve unintended medicine discrepancies, defined as differences between the home treatment
Autor:
A Rodriguez Delgado, C Gómez Peña, A Valle Ruiz de la Guardia, R Morón Romero, M Valle Corpas, A Caballero Romero, Mdc Gonzalez Medina, J Cabeza Barrera
Publikováno v:
European Journal of Hospital Pharmacy. 23:A212.1-A212
Background Oncology patients often have swallowing problems or dysphagia. Dysphagia is a frequent syndrome in patients with tumours involving the CNS, head and neck, and upper aerodigestive tract. This can be the initial symptom or related to the onc
Autor:
R Morón Romero, A Caballero Romero, A Rodriguez Delgado, G Rodriguez Torne, J Cabeza Barrera, C Lara Ramos, M Valle Corpas, MC González Medina, I Casas Hidalgo, D Blanquez Martinez
Publikováno v:
European Journal of Hospital Pharmacy. 23:A136.2-A136
Background Extravasation of cytostatic agents is one of the major complications in cancer treatment with anthracyclines. There is a lot of information about the management of extravasations with ‘classical’ anthracyclines but liposomal anthracycl